Announcements

We are pleased to share a selection of papers published in 2024 on the topic of colorectal cancer: prevention, precision, and progress, in the journal Cancers (ISSN: 2072-6694). Below is a list of high-quality articles that we believe you will find insightful and engaging.

1. “Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment”
by William H. Gmeiner
Cancers 2024, 16(5), 1029; https://doi.org/10.3390/cancers16051029
Available online: https://www.mdpi.com/2072-6694/16/5/1029

2. “The Impact of the Gut Microbiome, Environment, and Diet in Early-Onset Colorectal Cancer Development”
by Rui Dai, Bridget N. Kelly, Amarachi Ike, David Berger, Andrew Chan, David A. Drew, David Ljungman, David Mutiibwa, Rocco Ricciardi, Gerald Tumusiime et al.
Cancers 2024, 16(3), 676; https://doi.org/10.3390/cancers16030676
Available online: https://www.mdpi.com/2072-6694/16/3/676

3. “Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer”
by Nadia Saoudi González, Javier Ros, Iosune Baraibar, Francesc Salvà, Marta Rodríguez-Castells, Adriana Alcaraz, Ariadna García, Josep Tabernero and Elena Élez
Cancers 2024, 16(2), 412; https://doi.org/10.3390/cancers16020412
Available online: https://www.mdpi.com/2072-6694/16/2/412

4. “Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer”
by Keila S. Espinoza and Ashley J. Snider
Cancers 2024, 16(4), 789; https://doi.org/10.3390/cancers16040789
Available online: https://www.mdpi.com/2072-6694/16/4/789

5. “Obesity and Inflammatory Factors in the Progression of Early-Onset Colorectal Cancer”
by Alexandra N. Jones, Katharina M. Scheurlen, Anne Macleod, Hillary L. Simon and Susan Galandiuk
Cancers 2024, 16(7), 1403; https://doi.org/10.3390/cancers16071403
Available online: https://www.mdpi.com/2072-6694/16/7/1403

6. “Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence”
by Kun-Yu Tsai, Po-Shuan Huang, Po-Yu Chu, Thi Ngoc Anh Nguyen, Hsin-Yuan Hung, Chia-Hsun Hsieh and Min-Hsien Wu
Cancers 2024, 16(13), 2316; https://doi.org/10.3390/cancers16132316
Available online: https://www.mdpi.com/2072-6694/16/13/2316

7. “Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer”
by Alexander Sebastian Franzén, Abdelhadi Boulifa, Clarissa Radecke, Sebastian Stintzing, Martin J. Raftery and Gabriele Pecher
Cancers 2024, 16(2), 388; https://doi.org/10.3390/cancers16020388
Available online: https://www.mdpi.com/2072-6694/16/2/388

8. “Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives”
by Anne Jacobsen, Jürgen Siebler, Robert Grützmann, Michael Stürzl and Elisabeth Naschberger
Cancers 2024, 16(5), 890; https://doi.org/10.3390/cancers16050890
Available online: https://www.mdpi.com/2072-6694/16/5/890

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

We are pleased to announce the winner of the Cancers 2024 Outstanding Reviewer Award, Dr. Mohammad Hasanain.

The following is a short interview with Dr. Mohammad Hasanain:

1. Could you give us a brief introduction of yourself to the readers?
I was born and raised in Jaunpur, a small town in Uttar Pradesh, India. Growing up, I was always curious about how things work, especially the human body and diseases like cancer.
I completed my undergraduate studies in life sciences and began my scientific journey with a strong interest in the molecular mechanisms behind cancer progression. I pursued my Ph.D. in India, where I focused on studying the mechanism of action of novel anticancer compounds identified through screening. My research emphasized the roles of apoptosis and autophagy in promoting cancer cell death, specifically how the crosstalk between these two processes could be harnessed to develop more effective chemotherapeutic strategies. In January 2020, after completing my Ph.D., I moved to the United States to join the laboratories of Dr. Antonio Iavarone and Dr. Anna Lasorella at the Institute for Cancer Genetics, Columbia University, New York. There, I expanded my research into glioblastoma, aiming to understand the molecular landscape and tumor microenvironment that support this highly aggressive brain cancer. In September 2022, I continued working with the same group at the Sylvester Comprehensive Cancer Center, University of Miami Health System, following their relocation. Since then, my research has focused on investigating the self-renewing properties of glioma stem cells and the key drivers of glioblastoma growth and progression. I use advanced in vivo models to study the tumor microenvironment and its contribution to therapy resistance. My long-term research goals include developing robust mouse models of glioblastoma, identifying critical pathways involved in tumor initiation and progression, and translating these findings into novel therapeutic strategies for patients affected by this devastating disease.

2. What is your current research, and why did you choose this research field?
Right now, my research is focused on glioblastoma, a very aggressive and heartbreaking form of brain cancer. I am particularly interested in the glioma stem cells, which are a small population of cells within the tumor that can self-renew, resist treatment, and are often responsible for tumor recurrence. I am also studying the tumor microenvironment—basically, how the surroundings of the tumor help it survive and grow, even in the face of therapies. I chose this field because of urgent clinical need. Despite significant advances in cancer treatment, glioblastoma remains a disease with a very poor prognosis and limited therapeutic options. Although the complexity of the tumor, especially its heterogeneity and adaptability, presents a major challenge, it also serves as an opportunity to uncover novel insights that could lead to meaningful breakthroughs. I was drawn to this area not only for its scientific challenges but also for the potential impact our findings could have on patient care. Working in this field allows me to combine advanced techniques in cancer biology, stem cell research, and in vivo modeling to address questions that are both fundamental and translational. Ultimately, my goal is to identify new vulnerabilities in GBM that can be targeted with more effective therapies.

3. What are your opinions about the scientific publication market, and what do you think about the open access model?
Honestly, the scientific publishing world is a bit of a double-edged sword. On the one hand, it is how we share our hard-earned discoveries with the world. But on the other hand, it can feel like a system that is not always built for the benefit of science or scientists, especially when important research gets locked behind expensive paywalls. Traditional subscription-based models often limit access, creating barriers for researchers in underfunded institutions or developing countries, which ultimately slows down scientific progress and collaboration. That is why I strongly support the open access model. I think knowledge should be freely available to anyone who is curious, whether that is a scientist in a well-funded lab or a student in a small town with big dreams. Open access makes research more visible, more shareable, and ultimately, more impactful. And in fields like cancer research, where lives are literally on the line, we cannot afford delays in access to information. However, the current open access model still comes with its own set of challenges. The high article processing charges (APCs) required by many journals can be a major barrier, especially for early career researchers or those without strong financial support. It is not always fair that researchers have to pay so much just to share their work. We need better support systems and alternative funding mechanisms to make open access more inclusive and sustainable, not just for those with big grants or institutional backing. Furthermore, science is about discovery, collaboration, and hope. The more open we are with our knowledge, the faster we can move toward breakthroughs that truly make a difference. That is the future I want to be part of; one where science is accessible, equitable, and driven by the needs of people, not just the publishing industry.

4. Have you ever encountered any difficulties when you conduct research? How did you overcome them?
Absolutely, challenges in experimental setups are something every researcher faces, but I have come to understand that these moments are not exceptions in science; they are science. Especially in cancer research, where the biological systems we study are so complex and every patient sample is unique, difficulties are part of the process. I am working with primary patient-derived glioma models in vitro and in vivo, which can be unpredictable and sensitive. There were moments when experiments failed repeatedly, and it felt like the work was stuck. But those are the moments that really bring out the deeper values of science. The way I overcame those challenges was not by trying harder alone; it was through adopting a scientific temperament rooted in problem-solving, collaboration, and patience. What helped me overcome these challenges was developing a balanced approach, scientifically, mentally, and even physically. Meticulously, I took a step back and broke the problem down into smaller pieces, methodically troubleshooting each part. I documented everything carefully, repeated tests, and, most importantly, engaged with peers. I asked for input, shared what I was facing, and welcomed criticism and suggestions. That openness to feedback and willingness to learn from others always makes the difference. What is special about the scientific community is that we are united by a shared mission. We all want to understand disease better, to find answers, to improve lives. When I struggled in the lab, I was never truly alone; instead, I was part of a larger ecosystem of researchers, mentors, and even patients who believed in the same goal. That collective mindset helped me stay motivated. It turned frustration into curiosity and setbacks into learning experiences. What drives me, and I think many of us in this field, is knowing that our work has real meaning. We are not just moving pipettes and analyzing graphs; we are trying to give hope to people who are in some of the hardest battles of their lives. That understanding adds a layer of purpose that keeps me grounded and driven, even when the path gets tough. Science is not always fast or easy, but it is influential. And when we approach it with persistence, humility, and compassion for each other and for those we hope to help, we will always find a way forward.

5. What qualities do you think young scientists need? What qualities do you think reviewers need?
That is a great question, and if there is one thing I believe deeply, it is this: science is not just about data and discoveries; it is about individuals. The mindset we bring into the lab and the values we uphold as a community matter just as much as the results we publish. For young scientists, I would say the most important quality is inquisitiveness. It is that spark—the constant desire to ask “why,” to explore the unknown, and to challenge what we think we already understand. But along with curiosity, you need flexibility. Research is full of failure. Experiments do not always work. Papers get rejected. Grants do not come through. And that can be tough, especially early on. But these challenges are all part of the journey. What matters is how you respond, how you grow from those moments. Another quality I really value is humility. No one knows everything. Being open to learning, listening to others, and asking for help when you need it, that is what makes a good scientist even better. And of course, thirst—that deep, personal commitment to the work you are doing. Because when the days get long, and they will, it is that passion that keeps you going.
Now when it comes to reviewers, I think we sometimes forget how powerful that role is. Reviewers shape the tone of the scientific conversation. So, the essential thing we need is impartiality. A good review should be objective and based on the science, not personal bias. Then, there is productivity. It is easy to criticize, but it is much more meaningful to offer suggestions for improvement. We are not just gatekeepers—we are mentors at that moment, even if we never meet the authors. And conclusively, compassion. Behind every manuscript is a person, or a team, who worked incredibly hard. A little encouragement can go a long way, especially for young researchers who are just stepping into the field. We need a culture in science that lifts each other up. One that challenges everyone, yes, but with kindness, with rigor, and with the shared belief that we are all working toward something bigger than ourselves. Because at the end of the day, science is not a competition. It is a collective mission. And the more we support each other, the further we all go.

The 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) is a four-day congress dedicated to basic, preclinical, and translational cancer research across a wide breadth of topics. The conference will highlight the latest research and bring together members of the cancer research community to stimulate innovation and build knowledge, connections, and collaborations.

The following MDPI journals will be represented at the conference:

• Cancers;
• IJMS;
• Marine Drugs;
• Biomedicines;
• Healthcare;
• CIMB;
• Cells;
• Current Oncology;
• JPM;
• Neurology International;
• DNA.

If you are planning to attend the above conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #86 and answering any questions that you may have.

For more information about the conference, please visit the following website: https://2025.eacr.org.

We are pleased to share a selection of papers from the 2024 collection on the topic “Advances and Challenges in the Precision Management of Breast Cancer”, published in the journal Cancers (ISSN: 2072-6694). Below is a list of high-quality articles that we believe you will find insightful and engaging.

1. “Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions”
by Rohan Kalyan Rej, Joyeeta Roy and Srinivasa Rao Allu
Cancers 2024, 16(3), 552; https://doi.org/10.3390/cancers16030552
Available online: https://www.mdpi.com/2072-6694/16/3/552

2. “Gender-Specific Genetic Predisposition to Breast Cancer: BRCA Genes and Beyond”
by Virginia Valentini, Agostino Bucalo, Giulia Conti, Ludovica Celli, Virginia Porzio, Carlo Capalbo, Valentina Silvestri and Laura Ottini
Cancers 2024, 16(3), 579; https://doi.org/10.3390/cancers16030579
Available online: https://www.mdpi.com/2072-6694/16/3/579

3. “The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy”
by Corrado Tinterri, Bethania Fernandes, Alberto Zambelli, Andrea Sagona, Erika Barbieri, Simone Di Maria Grimaldi, Shadya Sara Darwish, Flavia Jacobs, Camilla De Carlo, Martina Iuzzolino et al.
Cancers 2024, 16(2), 376; https://doi.org/10.3390/cancers16020376
Available online: https://www.mdpi.com/2072-6694/16/2/376

4. “Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer”
by Natalia Andryszak, Daria Świniuch, Elżbieta Wójcik, Rodryg Ramlau, Marek Ruchała and Rafał Czepczyński
Cancers 2024, 16(3), 667; https://doi.org/10.3390/cancers16030667
Available online: https://www.mdpi.com/2072-6694/16/3/667

5. “De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadjuvant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy”
by Corrado Tinterri, Erika Barbieri, Andrea Sagona, Alberto Bottini, Giuseppe Canavese and Damiano Gentile
Cancers 2024, 16(6), 1169; https://doi.org/10.3390/cancers16061169
Available online: https://www.mdpi.com/2072-6694/16/6/1169

6. “High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer”
by Minna M. Jääskeläinen, Ritva Tumelius, Kirsi Hämäläinen, Kirsi Rilla, Sanna Oikari, Aino Rönkä, Tuomas Selander, Arto Mannermaa, Satu Tiainen and Päivi Auvinen
Cancers 2024, 16(3), 634; https://doi.org/10.3390/cancers16030634
Available online: https://www.mdpi.com/2072-6694/16/3/634

7. “Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets”
by Amalia Sofianidi, Ecaterina E. Dumbrava, Konstantinos N. Syrigos and Azadeh Nasrazadani
Cancers 2024, 16(6), 1139; https://doi.org/10.3390/cancers16061139
Available online: https://www.mdpi.com/2072-6694/16/6/1139

8. “Systemic and Local Strategies for Primary Prevention of Breast Cancer”
by Erin K. Zaluzec and Lorenzo F. Sempere
Cancers 2024, 16(2), 248; https://doi.org/10.3390/cancers16020248
Available online: https://www.mdpi.com/2072-6694/16/2/248

You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

We are thrilled to share the updated Exceptional Reviewers List 2025. This program was designed to recognize scholars who have consistently delivered exceptional review reports to our journal. Committed to fostering rigorous research and promoting knowledge exchange, Cancers (ISSN: 2072-6694) recognizes the significant role that our reviewers play in maintaining the quality and integrity of the articles that we publish. According to surveys conducted in 2024, 92% of our authors rate the peer-review process as good or excellent, which is thanks to our pool of excellent reviewers.

We wish to express our sincere appreciation to all the reviewers who have generously volunteered their time and expertise to assist Cancers’ peer-review process. Their dedication and attention to detail in evaluating manuscripts, offering valuable feedback and contributing to academic rigor, are truly commendable.

The Exceptional Reviewers List was introduced in April 2025. Each quarter, we select a group of outstanding reviewers, and we introduce them here.

Q1
Name: Dr. Mohammad Mofatteh
Affiliation: School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, UK
Interests: neurosurgery; surgery; neuroscience; global health; medical education
“Engaging in peer-review sharpens my critical thinking, keeps me at the forefront of cutting-edge research, and strengthens the scientific community by ensuring rigorous quality assurance. I prioritize delivering constructive feedback to elevate the clarity, validity, and impact of each manuscript.”

Name: Dr. Radu O. Minea
Affiliation: Department of Neurosurgery, Keck School of Medicine, USC, Los Angeles, CA 90089, USA
Interests: cancer biology; apoptosis; cell culture; cell signaling; cancer cell biology; cell proliferation; flow cytometry; gene expression; immunohistochemistry; Western blot analysis
“I have enjoyed working with the editors of the Cancers journal in my past interactions with them and I am committed to help with the peer-review process in the future.”

Name: Dr. Radoslaw Pach
Affiliation: Jagiellonian University Medical College, Krakow, Poland
Interests: oncological surgery; colorectal cancer; gastric cancer; thyroid surgery; hernia; laparoscopy
“I review for journals using my clinical and research expertise to assess oncology studies, focusing on rigor, clarity, and impact, and providing constructive, evidence-based feedback.”

Name: Dr. Giovanni Colonna
Affiliation: Medical Informatics Unit, AOU L. Vanvitelli, University of Campania, Piazzetta Sant’Aniello a Caponapoli 2, 80138 Naples, Italy
Interests: cancer biology; bioinformatics and computational biology; enzymes; proteins; PCR;
protein purification; protein expression; evolution; critical thinking; cancer cell biology
“Cancer research faces significant obstacles in accurately modeling the complexity of human tumors with current preclinical systems. From observational data, we cannot directly obtain the deep molecular causes without specific experimental data.”

Name: Prof. Dr. Lars Martin Wagner
Affiliation: Division of Pediatric Hematology/Oncology, Duke University, Durham, North Carolina
Interests: pediatric sarcoma; young adult sarcoma; clinical trials; sarcoma biology; treatment response; rare cancers; translational research

World Immunization Week, celebrated annually during the last week of April, is a global health awareness initiative highlighting the critical role of vaccines in protecting people of all ages against vaccine-preventable diseases.

On this momentous occasion, we are thrilled to present a thoughtfully selected compilation of articles and Special Issues that focus on the pioneering research and cutting-edge strategies in immunology and vaccination. We encourage readers to delve into these scholarly contributions and stand with us in our commitment to preserving and enhancing global immunization health.

Join us as we explore the latest findings and innovative methods that are shaping the future of immunization. Together, we can strive towards a world where every individual has access to the life-saving benefits of vaccines.

We hope that the established journals in the fields of biology life sciences and medicine and pharmacology at MDPI will provide a communication platform for innovative ideas regarding prevention and treatment.

“Lifestyle and Biochemical Parameters That May Hamper Immune Responses in Pediatric Patients After Immunization with the BNT162b2 mRNA COVID-19 Vaccine”
by Anthie Damianaki, Antonios Marmarinos, Margaritis Avgeris, Dimitrios Gourgiotis, Elpis-Athina Vlachopapadopoulou, Marietta Charakida, Maria Tsolia and Lydia Kossiva
Diseases 2025, 13(3), 78; https://doi.org/10.3390/diseases13030078

“Evaluating the Potential of Herbal Extracts as Treatment in Immune Thrombocytopenia: A Review of Evidence and Limitations”
by Russell W. Wiggins, Jihoo Woo, John Nicholas Cauba and Shizue Mito
Appl. Biosci. 2025, 4(1), 1; https://doi.org/10.3390/applbiosci4010001

“Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives”
by Ilaria Salvato and Antonio Marchini
Cancers 2024, 16(7), 1276; https://doi.org/10.3390/cancers16071276

“Unveiling Extramedullary Hematopoiesis: A Case Report Highlighting the Causes, Symptoms, and Management Strategies”
by Konstantinos Manganas, Aikaterini Xydaki, Angeliki Kotsiafti, Olympia Papakonstantinou and Sophia Delicou
Thalass. Rep. 2024, 14(2), 26-32; https://doi.org/10.3390/thalassrep14020004

“Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches”
by Natalie Fuchs, Longfei Zhang, Laura Calvo-Barreiro, Katarzyna Kuncewicz and Moustafa Gabr
J. Pers. Med. 2024, 14(1), 68; https://doi.org/10.3390/jpm14010068

“Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders”
by Yi Zhang, Anna-Lise Bissola, Jared Treverton, Michael Hack, Mark Lychacz, Sarah Kwok, Addi Arnold and Ishac Nazy
J. Clin. Med. 2024, 13(4), 1012; https://doi.org/10.3390/jcm13041012

“Immune Response to Respiratory Viral Infections”
by Antonella Gambadauro, Francesca Galletta, Alessandra Li Pomi, Sara Manti and Giovanni Piedimonte
Int. J. Mol. Sci. 2024, 25(11), 6178; https://doi.org/10.3390/ijms25116178

“Neutrophil Extracellular DNA Traps in Response to Infection or Inflammation, and the Roles of Platelet Interactions”
by William A. Chen and Danilo S. Boskovic
Int. J. Mol. Sci. 2024, 25(5), 3025; https://doi.org/10.3390/ijms25053025

“Host Immune Regulation in Implant-Associated Infection (IAI): What Does the Current Evidence Provide Us to Prevent or Treat IAI?”
by Zulipikaer Maimaiti, Zhuo Li, Chi Xu, Jun Fu, Li-Bo Hao, Ji-Ying Chen and Wei Chai
Bioengineering 2023, 10(3), 356; https://doi.org/10.3390/bioengineering10030356

“Airborne Pollen Calendar of Toluca City, Mexico”
by Maria Cid del Prado, Osvaldo Zarco-Cid del Prado, Hilda Adriana Guerrero-Parra and Karla Elisa Juárez Contreras
Aerobiology 2023, 1(1), 54-69; https://doi.org/10.3390/aerobiology1010005

“Innovative Therapies and Management of Complications in Hemoglobinopathies”	“Peptide-Based Vaccines: An Efficient Alternative to Combat Infectious Diseases and Drug Resistance”
“Immunotherapy in the Management of Hematologic Malignancy”	“Feature Review for Applied Biosciences”
“Advances in Transfusion Medicine and Immunological Research”	“Advancements in Artificial Intelligence for Bioaerosol Detection, Characterization, and Modeling”

We are pleased to announce that seven new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in February 2025. We wish our new members success in both their research and their efforts to develop the journal.

Name: Prof. Dr. Muy-Teck Teh
Affiliation: ¹ Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Barts; ² The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
Interests: molecular diagnostics; cancer biomarkers; transcriptomics; foxm1; qmids digital cancer test

Name: Prof. Dr. Thomas Ming Swi Chang
Affiliation: ¹ Artificial Cells and Organs Research Centre, Faculty of Medicine and Medical Sciences; ² McGill University, Montreal, QC H3G1Y6, Canada
Interests: artificial cells; biomaterials; blood substitutes; drug delivery; microencapsulation; enzyme engineering

Name: Dr. Dario Baratti
Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Interests: hyperthermic intraperitoneal chemotherapy; cytoreductive surgery; peritoneum tumor; peritoneal malignancies; colorectal cancer

Name: Dr. Chiara Laezza
Affiliation: Consiglio Nazionale delle Ricerche, IEOS, CNR, 80145 Naples, Italy
Interests: mevalonate pathway; prenylation proteins; cannabinoid and cancer; cell cycle; cancer-related biochemical pathways; cell proliferation; cell signaling; breast cancer; glioblastoma multiforme

Name: Prof. Dr. Cesare Gridelli
Affiliation: Division of Medical Oncology, S.G. Moscati Hospital, 83100 Avellino, Italy
Interests: lung cancer; non-small cell lung cancer; targeted therapies; immunotherapy

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office and provide the following files:

• A full academic CV;
• A short cover letter detailing your interest in the position.

World Health Day aims to draw global attention to pressing health challenges, reinforcing our commitment to the United Nations’ Sustainable Development Goal 3—ensuring healthy lives and promoting well-being for all.

This year’s theme, “Healthy Beginnings, Hopeful Futures” highlights the importance of maternal and infant health. Current estimates show that a woman dies every two minutes from preventable causes related to pregnancy and childbirth. Urgent action is needed to end preventable maternal and newborn deaths and to prioritize women’s long-term health and well-being.

To provide high-quality care before, during, and after childbirth, we must engage in critical discussions and foster collaboration among researchers, policymakers, and healthcare professionals. Health systems must evolve to address the full spectrum of maternal and newborn health issues—from obstetric complications to mental health conditions, noncommunicable diseases, and family planning.

In recognition of World Health Day 2025, we invite you to explore a curated selection of articles, journals, and Special Issues spanning multiple disciplines. These resources offer valuable insights into the complexities of maternal and infant health and outline actionable steps toward lasting, positive change.

Together, we can build a world where every mother and child have the opportunity for a healthy, hopeful future.

Maternal Health
“Relationship Between Plasma Acid Sphingomyelinase and Alteration in Taste and Smell as Indicator of Long COVID in Pregnant Women”
by Federico Fiorani, Giulia Moretti, Laura Cerquiglini, Chiara Gizzi, Giulia Gizzi, Paola Signorelli, Samuela Cataldi, Tommaso Beccari, Elisa Delvecchio, Claudia Mazzeschi et al.
Reports 2024, 7(4), 104; https://doi.org/10.3390/reports7040104
  
“Pregnant Women’s Perception of Gestational Anemia and Iron Supplements in Oman”
by Zalikha Khamis Al-Marzouqi, Nawal Said Alsereahi and Safiya Khalfan Al Maqbali
J. Oman Med. Assoc. 2024, 1(1), 10–22; https://doi.org/10.3390/joma1010003

“The Sri Lanka Mother and Newborn Growth (S-MaNGro) Cohort: Protocol of a Nationwide Prospective Study”
by Malshani Lakshika Pathirathna, Megumi Haruna, Satoshi Sasaki, Kaori Yonezawa, Yuriko Usui and Yasuhiro Hagiwara
Methods Protoc. 2024, 7(4), 61; https://doi.org/10.3390/mps7040061

“Gestational Trophoblastic Disease: Complete versus Partial Hydatidiform Moles”
by Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad and Robert Poppiti
Diseases 2024, 12(7), 159; https://doi.org/10.3390/diseases12070159

“Evaluating Thromboprophylaxis Strategies for High-Risk Pregnancy: A Current Perspective”
by Lucia Stančiaková, Kristína Brisudová, Ingrid Škorňová, Tomáš Bolek, Matej Samoš, Kamil Biringer, Ján Staško and Juraj Sokol
Pharmaceuticals 2024, 17(6), 773; https://doi.org/10.3390/ph17060773

“Caring for Pregnant Patients with Cancer: A Framework for Ethical and Patient-Centred Care”
by Alma Linkeviciute, Rita Canario, Fedro Alessandro Peccatori and Kris Dierickx
Cancers 2024, 16(2), 455; https://doi.org/10.3390/cancers16020455

“Histopathological Clues of Enhanced Inflammation in the Placental Tissue of Women with Chronic Venous Disease in Lower Limbs during Pregnancy”
by María Asunción Sánchez-Gil, Oscar Fraile-Martinez, Cielo García-Montero, María Del Val Toledo, Luis G. Guijarro, Juan A. De León-Luis, Coral Bravo, Raúl Díaz-Pedrero, Laura López-Gonzalez, Miguel A. Saez et al.
J. Pers. Med. 2024, 14(1), 87; https://doi.org/10.3390/jpm14010087

“Challenges Related to Acquisition of Physiological Data for Physiologically Based Pharmacokinetic (PBPK) Models in Postpartum, Lactating Women and Breastfed Infants—A Contribution from the ConcePTION Project”
by Martje Van Neste, Annick Bogaerts, Nina Nauwelaerts, Julia Macente, Anne Smits, Pieter Annaert and Karel Allegaert
Pharmaceutics 2023, 15(11), 2618; https://doi.org/10.3390/pharmaceutics15112618

“Umbilical Cord Diseases Affecting Obstetric and Perinatal Outcomes”
by Gabriele Tonni, Mario Lituania, Alessandro Cecchi, Elisa Carboni, Serena Resta, Maria Paola Bonasoni and Rodrigo Ruano
Healthcare 2023, 11(19), 2634; https://doi.org/10.3390/healthcare11192634

“Scientists’ Warning: Remove the Barriers to Contraception Access, for Health of Women and the Planet”
by Jan Greguš and John Guillebaud
World 2023, 4(3), 589–597; https://doi.org/10.3390/world4030036

“Trauma-Informed Care and Equity in Group Pregnancy Care for Women of Refugee Background: Reflections from the Workforce”
by Fran Hearn, Laura Biggs, Stephanie J. Brown, Ann Krastev, Josef Szwarc and Elisha Riggs
Trauma Care 2023, 3(3), 161–176; https://doi.org/10.3390/traumacare3030016

“Smoking Cessation Rates among Pregnant Women and Their Relapse Rates in the Postpartum Period in Samsun”
by Bektas Murat Yalcin, Tugba Kertmen and Muge Ustaoglu
J. Respir. 2023, 3(3), 118–129; https://doi.org/10.3390/jor3030012

“Effects of COVID-19 on Kenya’s Healthcare System: Healthcare Providers’ Experiences with Maternal Health Services Utilization in Coastal Kenya”
by Stephen Okumu Ombere and Agnetta Adiedo Nyabundi
World 2023, 4(1), 140–152; https://doi.org/10.3390/world4010010

Infant and Child Health
“Clinical Insight into Congenital Hypothyroidism Among Children”
by Hüseyin Anıl Korkmaz
Children 2025, 12(1), 55; https://doi.org/10.3390/children12010055

“Child and Adolescent Mental Health in a Period of Fewer COVID-19-Related Restrictions in an Urban Population in Germany”
by Anna Konopka, Amand Führer, Mascha Binder, Sophie Diexer, Thomas Frese, Michael Gekle, Matthias Girndt, Cornelia Gottschick, Jessica Hoell, Bianca Klee et al.
Psychiatry Int. 2024, 5(4), 718–737; https://doi.org/10.3390/psychiatryint5040050

“Differences in Farmers’ Market Patronage among Participants in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)”
by Renata Blumberg, Emily Fowler, Gabrielle Guerrero, Yeon Bai, Meena Mahadevan and Pankaj Lal
Dietetics 2024, 3(2), 179–190; https://doi.org/10.3390/dietetics3020015

“Maternal Depressive Symptoms in the First Year after Childbirth Predict Long-Term Developmental Risks in Sons and Daughters”
by Linda S. Pagani, Kianoush Harandian, Beatrice Necsa, Marie-Josée Harbec and George M. Tarabulsy
Int. J. Environ. Res. Public Health 2024, 21(3), 264; https://doi.org/10.3390/ijerph21030264

“Inflammatory Biomarker Profiles in Very Preterm Infants within the Context of Preeclampsia, Chorioamnionitis, and Clinically Diagnosed Postnatal Infection”
by Jordan T. Ewald, Baiba Steinbrekera, Jennifer R. Bermick, Donna A. Santillan, Tarah T. Colaizy, Mark K. Santillan and Robert D. Roghair
Pediatr. Rep. 2023, 15(3), 483–493; https://doi.org/10.3390/pediatric15030044

“A Pilot Randomised Controlled Trial Evaluating a Regenerative Epithelial Suspension for Medium-Size Partial-Thickness Burns in Children: The BRACS Trial”
by Anjana Bairagi, Zephanie Tyack, Roy Kimble, Dimitrios Vagenas, Steven M. McPhail and Bronwyn Griffin
Eur. Burn J. 2023, 4(1), 121–141; https://doi.org/10.3390/ebj4010012

“The Impact of the Early COVID-19 Global Pandemic on Children Undergoing Active Cancer Treatment and Their Parents”
by Andrew Tran, Sharon H. J. Hou, Caitlin Forbes, Sara Cho, Victoria J. Forster, Mehak Stokoe, Claire E. Wakefield, Lori Wiener, Lauren C. Heathcote, Gisela Michel et al.
Curr. Oncol. 2023, 30(2), 2441–2456; https://doi.org/10.3390/curroncol30020186

“Feature Advancements in Section “Childhood, Adolescent and Young Adult Oncology””	“Global Neonatal Screening: Expanding Horizons in Diagnostic Technologies”
“Healthy Lifestyle for Pregnant and Postpartum Women”	“Advanced Pediatric Drug Formulation Strategies”

MDPI is pleased to announce our participation in the 62nd ERA Congress, which will be held from 4 to 7 June 2025 in Vienna, Austria.

The 62nd ERA Congress will revolve around the theme of “Game Changers in Nephrology”. The seven main tracks can be explored via the following link: https://www.era-online.org/events/vienna-2025/scientific-programme/.

The following MDPI journals will be represented:

• Kidney and Dialysis;
• Journal of Personalized Medicine;
• Biomedicines;
• Cancers;
• Cells;
• Journal of Clinical Medicine;
• DNA;
• Journal of Molecular Pathology.

If you are attending 62nd ERA Congress, we invite you to visit us at booth X3.380. Our representatives, Mr. Peter Roth and Dr. Jennie Xu, will be available to discuss publishing opportunities, the benefits of open access, and our commitment to advancing geosciences research.

For more information about the conference, please visit its official website: https://www.era-online.org/events/vienna-2025/.